BridgeBio Pharma Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $46
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $43
BridgeBio Pharma Receives 'Buy' Rating Amid Positive Regulatory Outlook for Acoramidis
Scotiabank Initiates BridgeBio Pharma at Sector Outperform With $44 Price Target
Express News | BridgeBio Pharma Inc : Leerink Partners Cuts Target Price to $47 From $48
BridgeBio Pharma (NASDAQ:BBIO) Shareholders Have Endured a 49% Loss From Investing in the Stock Three Years Ago
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Optimistic Patent Litigation Outlook Strengthens Buy Rating for BridgeBio Pharma
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
BridgeBio Granted Perform Rating at Oppenheimer on Market Challenges
BridgeBio to Present Outcomes Data Through 42 Months From the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
Oppenheimer Initiates BridgeBio Pharma at Perform
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Express News | BridgeBio Pharma Inc - Topline Data Readout From Interim Analysis Expected in 2025
Express News | BridgeBio Completes Enrollment of Fortify, Phase 3 Registrational Study of Bbp-418 in Limb-Girdle Muscular Dystrophy Type 2I/R9 (Lgmd2I/R9)
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43